Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Rocket Pharmaceuticals, Inc.

< Previous 1 2 3 Next >
Rocket Pharmaceuticals Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals Announces Leadership Expansion to Support Company on Evolution Towards Commercial Stage
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Pyruvate Kinase Deficiency and Severe Leukocyte Adhesion Deficiency-I Programs at the 64th American Society of Hematology (ASH) Annual Meeting
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals Completes Acquisition of Renovacor
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals Announces Presentations Highlighting AAV and Lentiviral Gene Therapies at Upcoming Scientific Congresses
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals to Present at the 2022 Cell & Gene Meeting on the Mesa
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals to Present at Morgan Stanley 20th Annual Global Healthcare Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals Appoints Mayo Pujols as Chief Technical Officer and Strengthens Manufacturing Capabilities
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals to Present at William Blair Biotech Focus Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
Rocket Pharmaceuticals Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
Tickers RCKT
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.